CompletedNCT01716975
EVP-6124 Added to Antipsychotics for Cognition in Schizophrenia
About this title
Read the official source — NCT01716975Medication studyAges 18–50Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- Phoenixville and 105 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 767
- Sponsor
- FORUM Pharmaceuticals Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, United Kingdom, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT01716975
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenixville, United States · Little Rock, United States · Cerritos, United States
103 more locations
- Chino, United States
- Costa Mesa, United States
- Garden Grove, United States
- Glendale, United States
- Norwalk, United States
- Oakland, United States
- Oakland Park, United States
- Oceanside, United States
- Riverside, United States
- San Diego, United States
- San Gabriel, United States
- Santa Ana, United States
- Sherman Oaks, United States
- Washington D.C., United States
- Bradenton, United States
- Miami, United States
- Miami Springs, United States
- North Miami, United States
- Orlando, United States
- Marietta, United States
- Smyrna, United States
- Chicago, United States
- Oak Brook, United States
- Oak Park, United States
- Wichita, United States
- Lake Charles, United States
- Shreveport, United States
- Rockville, United States
- Boston, United States
- Saint Charles, United States
- St Louis, United States
- Lincoln, United States
- Princeton, United States
- Jamaica, United States
- New York, United States
- Rochester, United States
- Charlotte, United States
- Beachwood, United States
- Oklahoma City, United States
- Jenkintown, United States
- Austin, United States
- Dallas, United States
- Salt Lake City, United States
- Bellevue, United States
- Richland, United States
- Spokane, United States
- Banfield, Argentina
- Caba, Argentina
- Mendoza, Argentina
- Rosario, Argentina
- Santiago del Estero, Argentina
- Adelaide, Australia
- Mount Claremont, Australia
- Salvader, Brazil
- Belo Horizonte, Brazil
- Curitiba, Brazil
- Medellín, Colombia
- Barranquilla, Colombia
- Pereira, Colombia
- Bogota D.C., Colombia
- Florence, Italy
- Milan, Italy
- Ban, Italy
- Barl, Italy
- Catania, Italy
- Lucca, Italy
- Pisa, Italy
- Roma, Italy
- Monterrey, Mexico
- Mexico City, Mexico
- San Luis Potosí City, Mexico
- Bełchatów, Poland
- Chełmno, Poland
- Karakow, Poland
- Kielce, Poland
- Kotarbinskiego, Poland
- Sosnowiec, Poland
- Torun, Poland
- Wroclaw, Poland
- Campulung Muscel, Romania
- Oradea, Romania
- Cluj-Napoca, Romania
- Palazu Mare, Romania
- Iași, Romania
- Târgu Mureş, Romania
- Bucharest, Romania
- Saint Petersburg, Russia
- Smolensk, Russia
- Moscow, Russia
- Samara, Russia
- Yaroslavl, Russia
- Vil. Stepanivka, Ukraine
- Dnipropetrovsk, Ukraine
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Poltava, Ukraine
- Vinnytsia, Ukraine
- Cambridge, United Kingdom
- Newcastle upon Tyne, United Kingdom
- Exeter, United Kingdom
- London, United Kingdom
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is FORUM Pharmaceuticals Inc.
Did this study involve medication?
Yes. The study involved medication, including EVP-6124 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
